European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

Peter Valent*, Karin Hartmann, Patrizia Bonadonna, Wolfgang R. Sperr, Marek Niedoszytko, Olivier Hermine, Hanneke C. Kluin-Nelemans, Karl Sotlar, Gregor Hoermann, Boguslaw Nedoszytko, Sigurd Broesby-Olsen, Roberta Zanotti, Magdalena Lange, Michael Doubek, Knut Brockow, Ivan Alvarez-Twose, Judit Varkonyi, Selim Yavuz, Gunnar Nilsson, Deepti RadiaClive Grattan, Juliana Schwaab, Theo Gülen, Hanneke N.G. Oude Elberink, Hans Hägglund, Frank Siebenhaar, Emir Hadzijusufovic, Vito Sabato, Jiri Mayer, Andreas Reiter, Alberto Orfao, Hans Peter Horny, Massimo Triggiani, Michel Arock

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

46 Downloads (Pure)


In 2002, the European Competence Network on Mastocytosis (ECNM) was launched as a multidisciplinary collaborative initiative to increase the awareness and to improve diagnosis and management of patients with mast cell (MC) disorders. The ECNM consists of a net of specialized centers, expert physicians, and scientists who dedicate their work to MC diseases. One essential aim of the ECNM is to timely distribute all available information about the disease to patients, doctors, and scientists. In the past 20 years, the ECNM has expanded substantially and contributed successfully to the development of new diagnostic concepts, and to the classification, prognostication, and treatments of patients with mastocytosis and MC activation disorders. The ECNM also organized annual meetings and several working conferences, thereby supporting the development of the World Health Organization classification between 2002 and 2022. In addition, the ECNM established a robust and rapidly expanding patient registry and supported the development of new prognostic scoring systems and new treatment approaches. In all projects, ECNM representatives collaborated closely with their U.S. colleagues, various patient organizations, and other scientific networks. Finally, ECNM members have started several collaborations with industrial partners, leading to the preclinical development and clinical testing of KIT-targeting drugs in systemic mastocytosis, and some of these drugs received licensing approval in recent years. All these networking activities and collaborations have strengthened the ECNM and supported our efforts to increase awareness of MC disorders and to improve diagnosis, prognostication, and therapy in patients.

Original languageEnglish
JournalJournal of Allergy and Clinical Immunology: In Practice
Issue number6
Pages (from-to)1706-1717
Publication statusPublished - Jun 2023


  • ECNM
  • Mast cell activation disorders
  • Mast cells
  • Mastocytosis
  • MCAS


Dive into the research topics of 'European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives'. Together they form a unique fingerprint.

Cite this